EcoDrugPlus

Plasminogen Activator, Tissue Type

Ensembl ID : ENSLOCG00000015608
Gene Symbol: PLAT
1 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSLOCG00000018282
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSLOCG00000011097
Gene Symbol: PDGFRB
3 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSLOCG00000011442
Gene Symbol: PDGFB
2 Cross references
261 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSLOCG00000005649
Gene Symbol: PLK1
4 Cross references
189 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSLOCG00000010729
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSLOCG00000000267
Gene Symbol: PARP2
1 Cross references
185 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSLOCG00000015798
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSLOCG00000010661
Gene Symbol: PARP3
3 Cross references
199 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSLOCG00000014348
Gene Symbol: PORCN
3 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSLOCG00000004752
Gene Symbol: KCNMA1
3 Cross references
321 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSLOCG00000004166
Gene Symbol: KCNN4
2 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).